Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences, Inc
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 8 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C
To compare the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for 12 weeks as measured by the proportion of sub...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A clinical study to provide idelalisib to subjects previously treated with GS-9820
The primary objective of this study is to provide idelalisib to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A phase 1 study to evaluate GS-5829 alone and in combination with enzalutamide in patients with metastatic castrate-resistant prostate cancer
Dose Escalation: Characterize the safety/tolerability of GS-5829 as a single agent and in combination with enzalutamide (enz) in subjects with mCRPC; determine the MTD of GS-5829 as a single agent and...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic
The primary objective of this study is to evaluate the long-term safety of darusentan in subjects with RHTN despite treatment with full doses of three or more antihypertensive medications, including a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
The purpose of this study is to test the effectiveness of switching from ABC/3TC to F/TAF FDC versus continuing on ABC/3TC in HIV-1 infected subjects who are virologically suppressed. The safety and how well both the F/TAF FDC and ABC/3TC are tolerated will also be evaluated
To evaluate the efficacy of switching ABC/3TC to F/TAF versus maintaining ABC/3TC in HIV-1 infected subjects who are virologically suppressed on regimens containing ABC/3TC as determined by the propor...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A long-term study to follow patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial
To assess the durability of sustained virologic response (SVR) following treatment in a Gilead-sponsored Hepatitis C Study
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
Study for Efficacy and Tolerability of Entospletinib in Combination with Corticosteroids as First-Line Therapy in (cGVHD)
To evaluate the effect of ENTO on the best overall response rate (BORR) as assessed by the NIH cGVHD Activity Assessment (NCAA) by 24 weeks in the setting of add-on to systemic corticosteroids as part...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects aged ≥ 60 years who are virologically suppressed
-To evaluate the safety of E/C/F/TAF relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, H...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study to test the safety, tolerability and how well viral suppression is maintained of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) in HIV-1 infected subjects who are virologically suppressed and harbor the archived isolated NRTI resistance mutation M184V/M184I. Estudio para probar la seguridad, tolerabilidad y mantenimiento de la supresión viral al cambiar a una combinación de dosis fija (CDF) de elvitegravir / cobicistat / emtricitabina / tenofovir alafenamide (E/C/F/TAF) en sujetos infectados por VIH-1 que estén virológicamente suprimidosportadores de la mutación aislada y archivada M184V/M184I de resistencia a los ITIAN
To evaluate the efficacy of E/C/F/TAF fixed dose combination (FDC) after switching from a stable regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent in maintaining HIV-1 RNA < 5...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
Program to Give the Drug Aztreonamn Lysine for Inhalation to Canadian Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease Progression
The primary objective of this study is to provide expanded access to AZLI 75 mg prior to its commercial availability and establishment of reimbursement programs through Provincial Ministries of Health...
Country
None
organs
None
Specialty
None
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next